Pharvaris N.V. PHVS 深 滬
已收盤 08-15 16:00:00 美东时间
22.30
-0.690
-3.00%
華盛通- 最 高23.7317
- 今 開23.19
- 成交量 16.74万股
- 最 低 22.07
- 昨 收 22.99
- 總市值 12.15亿
- 52周最高 26.33
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 11.51
- 委 比 96.85%
- 總股本 5449.31万
- 歷史最高 42.86
- 量 比 2.17
- 振 幅 7.23%
- 歷史最低 1.77
- 每 手 1
- 風險率 4.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多JMP Securities Maintains Market Outperform on Pharvaris, Lowers Price Target to $52
JMP Securities analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and lowers the price target from $55 to $52.
08-13 22:21
Pharvaris Q2 EPS $(0.94) Misses $(0.87) Estimate
Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.94) per share which missed the analyst consensus estimate of $(0.87) by 8.05 percent. This is a 59.32 percent decrease over losses of $(0.59) per share from the
08-13 04:41
Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update
Pharvaris reported progress on its late-stage clinical trials for deucrictibant, including RAPIDe-3 (on-demand treatment for HAE attacks, with topline results expected in 4Q2025), CHAPTER-3 (prophylaxis for HAE attacks, with results in 2H2026), and CREAATE (treatment for AAE-C1INH attacks, set to begin by year-end 2025). The company strengthened its financial position with a $201 million public offering, extending its cash runway into 1H2027. Pha...
08-12 20:05
Pharvaris prices $175M securities offering
Pharvaris (NASDAQ:PHVS) priced an underwritten offering of 8.25 million shares at $20 each and 500,000 pre-funded warrants at $19.99 each, raising around $175 million in gross proceeds. The company al...
07-23 13:20
Pharvaris shares are trading lower after the company announced a $150 million proposed public offering.
Pharvaris shares are trading lower after the company announced a $150 million p...
07-23 04:24
Pharvaris Announces Proposed Public Offering of Ordinary Shares
Pharvaris N.V., a biopharmaceutical company developing oral bradykinin B2 receptor antagonists for angioedema, plans to offer and sell $150 million of ordinary shares in an underwritten public offering, with an option for up to an additional $22.5 million. Proceeds will fund late-stage clinical programs, U.S. sales and marketing team hiring, commercialization, and general corporate purposes. Morgan Stanley, Leerink Partners, Cantor, Oppenheimer &...
07-22 20:05
美股周涨跌榜 | 加密货币概念股SharpLink周涨71%；CoreWeave周内暴跌23.8%，分析师喊话公司估值似乎过高
加密货币股SharpLink周涨71%；MP周涨超41%，公司与美国国防部签署战略合作协议；CoreWeave周内暴跌23.8%，分析师喊话公司估值似乎过高>>
07-12 10:03
Pharvaris Anticipates Reporting Topline Data From Rapide-3 In Q4 Of 2025; Expects To Submit NDA With FDA In H1 Of 2026
Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary
07-10 18:52
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
Pharvaris plans to submit the NDA for its deucrictibant IR capsule to the U.S. FDA in 1H2026 for the on-demand treatment of HAE attacks, following the expected topline data announcement from the RAPIDe-3 pivotal Phase 3 study in Q4 2025.
07-10 10:50
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
Pharvaris, a biopharmaceutical company, announced the acceptance of six abstracts for poster presentations at the US Hereditary Angioedema Association's 2025 National Summit in Baltimore. The presentations focus on the long-term safety and efficacy of oral deucrictibant for treating and preventing hereditary angioedema (HAE) attacks, as well as its impact on patients' quality of life. The abstracts will be presented on July 11, 2025, with details...
06-27 10:50
